Comparably, the induction of Bip and consistent rise in CHOP expression was observed in all prostate cancer cells during dose-dependent treatments of TA, which was further affirmed from potential studies at both gene and protein levels (Figure 2A,B). This evidence concerns the gene DDIT3 and prostate carcinoma.